| abstract |
The present invention provides inhibitors capable of binding to a member of the S1PR receptor group comprised of S1PR2 and S1PR5 with a dissociation constant of 5x10 -7 mol/l or smaller for treating neuronal damage, specifically an antibody, an antibody fragment, an antibody-like molecule, a nucleic acid aptamer or an oligopeptide with 6 to 30 amino acid residues in length. Similarly, an interfering RNA or an antisense modulator of gene expression of G13 or a member of the S1PR receptor group described above are provided for treating of neuronal damage. |